Literature DB >> 2060081

Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds.

G Jansen1, G R Westerhof, I Kathmann, G Rijksen, J H Schornagel.   

Abstract

5,10-Dideazatetrahydrofolic acid (DDATHF) is a potent inhibitor of glycinamide ribonucleotide transformylase, one of the folate-dependent key enzymes in de novo purine biosynthesis. The present report demonstrates that multiple membrane-transport routes may be involved in the cellular uptake of DDATHF. These routes include the classic reduced folate carrier and a membrane-associated folate-binding protein (mFBP). The role of an mFBP in the uptake of DDATHF was suggested from observations that (a) the mFBP showed a very high binding affinity for DDATHF, (b) murine and human leukemia cells expressing an mFBP were highly sensitive to growth inhibition by DDATHF, and (c) protection against this growth inhibition could be achieved using folic acid rather than reduced folate compounds.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060081     DOI: 10.1007/bf00689699

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

1.  Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA.

Authors:  M Ratnam; H Marquardt; J L Duhring; J H Freisheim
Journal:  Biochemistry       Date:  1989-10-03       Impact factor: 3.162

2.  Analogs of tetrahydrofolate directed at folate-dependent purine biosynthetic enzymes. Characteristics of mediated entry and transport-related resistance in L1210 cells for 5,10-dideazatetrahydrofolate and two 10-alkyl derivatives.

Authors:  F M Sirotnak; G M Otter; J R Piper; J I DeGraw
Journal:  Biochem Pharmacol       Date:  1988-12-15       Impact factor: 5.858

3.  Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.

Authors:  G Jansen; J H Schornagel; G R Westerhof; G Rijksen; D R Newell; A L Jackman
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

4.  Growth inhibition by homofolate in tumor cells utilizing a high-affinity folate binding protein as a means for folate internalization.

Authors:  G B Henderson; B P Strauss
Journal:  Biochem Pharmacol       Date:  1990-06-15       Impact factor: 5.858

5.  Purification, properties, and immunological characterization of folate-binding proteins from human leukemia cells.

Authors:  E Sadasivan; M da Costa; S P Rothenberg; L Brink
Journal:  Biochim Biophys Acta       Date:  1987-07-16

6.  Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells.

Authors:  J J McGuire; A F Sobrero; J B Hynes; J R Bertino
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

7.  Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.

Authors:  H Diddens; D Niethammer; R C Jackson
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

8.  Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells.

Authors:  P C Elwood
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

9.  Properties of a folate binding protein (FBP) isolated from porcine kidney.

Authors:  B A Kamen; J D Caston
Journal:  Biochem Pharmacol       Date:  1986-07-15       Impact factor: 5.858

10.  Folate and methotrexate interactions in the rat kidney.

Authors:  J C Deutsch; J F Kolhouse
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

View more
  3 in total

1.  A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.

Authors:  S Laohavinij; S R Wedge; M J Lind; N Bailey; A Humphreys; M Proctor; F Chapman; D Simmons; A Oakley; L Robson; L Gumbrell; G A Taylor; H D Thomas; A V Boddy; D R Newell; A H Calvert
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.

Authors:  E Erba; S Sen; C Sessa; F L Vikhanskaya; M D'Incalci
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

3.  Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.

Authors:  S Sen; E Erba; M D'Incalci; F Bottero; S Canevari; A Tomassetti
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.